Clinical Trial: Phase I Study Of Vincristine, Doxorubicin, And Dexamethasone (VXD) Plus Ixazomib In Adults With Relapsed Or Refractory Acute Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia

Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional

Official Title: Phase I Study Of Vincristine, Doxorubicin, And Dexamethasone (VXD) Plus Ixazomib In Adults With Relapsed Or Refractory Acute Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Lymphoma Or Safety, tolerability will be assessed by number of participants with adverse events.



Original Primary Outcome: Same as current

Current Secondary Outcome: To determine the optimal dose of MLN9708 [ Time Frame: Baseline and 8 weeks ]

Optimal dose will be assessed by number of participants with adverse events.


Original Secondary Outcome: Same as current

Information By: Medical College of Wisconsin

Dates:
Date Received: June 5, 2013
Date Started: October 2013
Date Completion: August 2018
Last Updated: February 10, 2016
Last Verified: February 2016